BeiGene
.png){kind=logo}
Chinese biotechnology company
BeiGene, Ltd.
| Type | Public |
|---|---|
| Traded as | NASDAQ: BGNE , Template:HKEX |
| Key people | John V. Oyler (CEO) |
| Industry | Biotechnology |
| Products | Cancer treatments |
BeiGene, Ltd. is a global, commercial-stage biotechnology company focused on developing and commercializing innovative molecularly targeted and immuno-oncology drug candidates for the treatment of cancer. The company was founded in 2010 by John V. Oyler and Xiaodong Wang and is headquartered in Beijing, China.
History[edit]
BeiGene was established in 2010 with the aim of creating a world-class biotechnology company in China. The company has since expanded its operations globally, with offices and facilities in the United States, Australia, and various other countries.
Research and Development[edit]
BeiGene's research and development efforts are primarily focused on oncology. The company has a broad pipeline of drug candidates, including both small molecules and biologics. Key areas of research include immuno-oncology, molecularly targeted therapy, and combination therapy.
Products[edit]
BeiGene has developed several drug candidates that are in various stages of clinical development. Some of the notable products include:
- Brukinsa (zanubrutinib): A Bruton's tyrosine kinase (BTK) inhibitor for the treatment of mantle cell lymphoma and other B-cell malignancies.
- Tislelizumab: An anti-PD-1 antibody for the treatment of various types of cancer.
Collaborations and Partnerships[edit]
BeiGene has entered into several strategic collaborations and partnerships with leading pharmaceutical companies to advance its drug development programs. These partnerships include collaborations with companies such as Celgene, Amgen, and Novartis.
Stock Market[edit]
BeiGene is publicly traded on the NASDAQ under the ticker symbol BGNE and on the Hong Kong Stock Exchange under the ticker symbol 6160.
See also[edit]
Related pages[edit]
This article is a biotechnology stub. You can help WikiMD by expanding it!
Ad. Transform your health with W8MD Weight Loss, Sleep & MedSpa
Tired of being overweight?
Special offer:
Budget GLP-1 weight loss medications
- Semaglutide starting from $29.99/week and up with insurance for visit of $59.99 and up per week self pay.
- Tirzepatide starting from $45.00/week and up (dose dependent) or $69.99/week and up self pay
✔ Same-week appointments, evenings & weekends
Learn more:
- GLP-1 weight loss clinic NYC
- W8MD's NYC medical weight loss
- W8MD Philadelphia GLP-1 shots
- Philadelphia GLP-1 injections
- Affordable GLP-1 shots NYC
|
WikiMD Medical Encyclopedia |
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
